Your Search Results

TEER in complex tricuspid regurgitation - LIVE case

14 Feb 2026 – From PCR Tokyo Valves 2026

A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.

Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.

LIVE Educational Case...

TEER in complex tricuspid regurgitation - LIVE case

Hot topics and evidence on structural interventions in 2025 and 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Hot topics and evidence on structural interventions in 2025 and 2026

Prevention and management of TAVI complications

14 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...

Prevention and management of TAVI complications

Primary mitral TEER in small anatomy - LIVE case

15 Feb 2026 – From PCR Tokyo Valves 2026

An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).

One Pascal ACE device was implanted.

LIVE Educational Case from Nagoya...

Primary mitral TEER in small anatomy - LIVE case

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.